Medical Device News Magazine

ZetrOZ Systems Reports sam® Dramatically Improves the Treatment of Soft Tissue, Arthritis and Joint Issues Without Requiring Surgery or Pain Medication

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

July 15, 2020

ZetrOZ System reports sam® provides effective and safe treatment of soft tissue, arthritis and joint issues without the need for surgery or pain medication. The wearable device does so by stimulating blood flow for several hours per day to a localized region, delivering a powerful flow of nutrients to the site of an injury.

ZetrOZ Systems reports sam® administers 1.3 watts of low-intensity ultrasound energy at 3 megahertz frequency to accelerate biological healing processes and reduce pain. Harnessing the sustained delivery of low-intensity acoustic waves, the device stimulates the body’s natural repair process.

sam® is a safe and effective approach to healing tissue and easing pain. Instead of subjecting patients to time-consuming surgery with a lengthy recovery time and costly pain medication, the device gently massages users’ cells to promote collagen matrix production and cellular replication to heal damaged tissue.

sam® provides ultrasonic waves that penetrate five centimeters into tissue. This process improves circulation, oxygen and nutrient delivery. It also facilitates the removal of waste products, such as lactic acid, from the site of a musculoskeletal injury. In addition, sam® stimulates the tissue remodeling process. These processes give the device the unique ability to inhibit the inflammatory response and treat the injury itself – not just mask pain.

These are some of the reasons why sam® is the only continuous treatment, wearable mechanobiological device cleared by the FDA to treat deep tissue targets like knees, elbows, back and neck injuries.

Unlike traditional ultrasound treatments, sam® is FDA approved to provide treatment for four hours per day, versus 20 minutes per day. This expanded duration greatly improves the device’s ability to foster healing and pain relief. Additionally, traditional therapeutic ultrasound requires administration by a specialist onsite, thereby limiting the frequency of treatments. sam®, on the other hand, is easy and safe for patients to use at home on a daily basis – further increasing the treatment’s positive impact.

Transcutaneous Electrical Nerve Stimulation (TENS) controls pain by using electrical currents to stimulate nerves and block pain signals from being sent to the brain. While TENS and sam® have both proven successful in clinical studies for relieving pain, only sam® has the ability to accelerate the natural healing process through mechanical stimulation.

“We developed sam® to help people suffering from injuries and chronic pain break free from the traditional constraints of surgery and pain medication. While the treatment is highly effective, it is a natural, drug-free way to heal soft tissue and provide desperately needed pain relief – allowing users to reclaim their lives,” said George Lewis, chief executive officer of ZetrOZ Systems.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”